Compare FBRT & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBRT | OMER |
|---|---|---|
| Founded | 2012 | 1994 |
| Country | United States | United States |
| Employees | 223 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 701.9M | 772.8M |
| IPO Year | N/A | 2008 |
| Metric | FBRT | OMER |
|---|---|---|
| Price | $9.04 | $14.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $11.50 | ★ $32.50 |
| AVG Volume (30 Days) | 587.9K | ★ 1.0M |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | ★ 15.83% | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | $12.34 | N/A |
| Revenue Next Year | $4.95 | $233.22 |
| P/E Ratio | $13.56 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.24 | $2.95 |
| 52 Week High | $11.84 | $17.65 |
| Indicator | FBRT | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 51.56 | 60.96 |
| Support Level | $8.91 | $10.82 |
| Resistance Level | $9.26 | $15.32 |
| Average True Range (ATR) | 0.19 | 0.61 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 24.58 | 56.71 |
Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. The Company's operations are organized into two business units: (i) Commercial Real Estate Financing, and (ii) Agency Business. Its four reporting segments are as follows: The real estate debt business, The Agency Business, The commercial real estate conduit business, and The real estate owned business.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.